Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

CAR T-Cells Shown Effective in Long-Term Studies

Results from two clinical studies of engineered immune system cells show patients continue to respond their treatments after 6 months or more. . . . → Read More: CAR T-Cells Shown Effective in Long-Term Studies

Cell Programming Company Raises $49.5M in Early Funds

A start-up enterprise creating add-on treatments that program the effects of cell and gene therapies is raising $49.5 million in its first venture funding round. . . . → Read More: Cell Programming Company Raises $49.5M in Early Funds

FDA Approves Precision Solid Tumor Cancer Diagnostics

The Food and Drug Administration approved genomic tests for solid tumor cancers that identify the most promising available therapies matched to the tumor’s genetic mutations. . . . → Read More: FDA Approves Precision Solid Tumor Cancer Diagnostics

Trial to Test Ultrasound/MRI for Brain Cancer

A developer of a technology that combines ultrasound and MRI scans plans to begin a clinical trial of its techniques to improve delivery of drugs to treat a form of brain cancer. . . . → Read More: Trial to Test Ultrasound/MRI for Brain Cancer

Genome Editing Enhances CAR T-Cells to Fight Cancer

A process using genome editing is shown to bolster cancer-fighting properties of T-cells from the immune system already modified to attack cancer cells. . . . → Read More: Genome Editing Enhances CAR T-Cells to Fight Cancer

Biotech, Cancer Center Partner on T-Cell Research

A developer of cancer diagnostics and treatments is collaborating with Moffitt Cancer Center to advance therapies for ovarian cancer with T-cells from the immune system. . . . → Read More: Biotech, Cancer Center Partner on T-Cell Research

Biotech Licenses Mayo Clinic Microbiome Research

A biotechnology company developing therapies with specialized gut microbes is licensing research from the Mayo Clinic on these microbes’ effects with autoimmune diseases. . . . → Read More: Biotech Licenses Mayo Clinic Microbiome Research

Trial Underway Testing Personal RNA Cancer Drug

A clinical trial is underway testing a treatment for solid tumor cancers derived from messenger RNA, genetic material with protein coding instructions for cells. . . . → Read More: Trial Underway Testing Personal RNA Cancer Drug

Alliance Exploring Microbiome on Cancer Immunotherapy

A biotechnology company and two research institutes are collaborating on a study of a proposed cancer treatment that targets the microbiome, communities of bacteria in the human body. . . . → Read More: Alliance Exploring Microbiome on Cancer Immunotherapy

Zymeworks, Janssen in $1.45B Antibody Licensing Deal

Janssen Biotech, a division of drug maker Johnson & Johnson, is acquiring technologies that make it possible to create synthetic antibodies that hit multiple targets. . . . → Read More: Zymeworks, Janssen in $1.45B Antibody Licensing Deal